パンクロニウムブロミド

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H301：飲み込むと有毒

• 注意書き

  P301+P310：飲み込んだ場合：直ちに医師に連絡すること。

パンクロニウムブロミド 価格

MSDS Information

• Pancuronium bromide

パンクロニウムブロミド 化学特性,用途語,生産方法

• 溶解性

  水に溶ける。

• 用途

  アセチルコリン受容体遮断作 用を示します。

• 用途

  アセチルコリン受容体遮断作 用を示します。

• 効能

  神経筋遮断薬

• 説明

  Pancuronium bromide, a bisquaternary amine and the first steroid N MBA used clinically, was developed by Savege and Hewitt and marketed in 1964. The intubating dose is 0.1mgkg–1, which takes 3-4min to reach its maximum effect. The clinical duration of action of the drug is long, especially in the presence of potent inhalational agents or renal dysfunction, as 60% of a dose of the drug is excreted unchanged through the kidneys. I t is also deacetylated in the liver; some of the metabolites have neuromuscular blocking properties.
  Pancuronium does not stimulate histamine release; however, it has direct vagolytic and sympathomimetic effects which may cause tachycardia and hypertension. It slightly inhibits plasma cholinesterase and therefore potentiates any drug metabolised by this enzyme, such as suxamethonium and mivacurium.

• 化学的特性

  Light Beige Solid

• 使用

  Pancuronium Bromide has been used as an analgesic in various experiments.

• 定義

  ChEBI: A bromide salt consisting of two bromide ions and one pancuronium dication.

• 生物学の機能

  Pancuronium bromide (Pavulon) is a synthetic bisquaternary agent containing a steroid nucleus (amino steroid), as denoted by the -curonium suffix. It is five times as potent as d-tubocurarine. Unlike d-tubocurarine, it does not release histamine or block ganglionic transmission. Like d-tubocurarine, it has a moderately long onset (2.9 minutes) and duration of action (110 minutes). Pancuronium and its metabolite are eliminated in the urine.

• 生物活性

  Nicotine (neuromuscular) antagonist. Skeletal muscle relaxant.

• 薬理学

  Pancuronium bromide, a bisquaternary amine and the first steroid NMBA used clinically, was developed by Savege and Hewi and marketed in 1964. The intubating dose is 0.1 mg kg–1, which takes 3–4min to reach its maximum effect. The clinical duration of action of the drug is long, especially in the presence of potent inhalational agents or renal dysfunction, as 60% of a dose of the drug is excreted unchanged through the kidneys. I t is also deacetylated in the liver; some of the metabolites have neuromuscular blocking properties.
  Pancuronium does not stimulate histamine release; however, it has direct vagolytic and sympathomimetic effects which may cause tachycardia and hypertension. It slightly inhibits plasma cholinesterase and therefore potentiates any drug metabolised by this enzyme, such as suxamethonium and mivacurium.

• 臨床応用

  As indicated, the principal use of pancuronium bromideis as an adjunct to anesthesia, to induce relaxation of skeletalmuscle, but it is also used to facilitate the managementof patients undergoing mechanical ventilation. Only experiencedclinicians equipped with facilities for applyingartificial respiration should administer it, and the dosageshould be adjusted and controlled carefully.

• 安全性プロファイル

  A deadly poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx and Brí.

• 純化方法

  The bromide forms odourless crystals with a bitter taste which are purified through acid-washed Al2O3 and eluted with isoPrOH/EtOAc (3:1) to remove impurities (e.g. the monomethobromide) and eluted with isoPrOH to give the pure dibromide which is recrystallised from CH2Cl2/Me2CO or isoPrOH/Me2CO. It is soluble in H2O (10%) and CHCl3 (3.3%) at 20o. It is a non-depolarising muscle relaxant. [Buckett et al. J Med Chem 16 1116 1973.]

パンクロニウムブロミド 上流と下流の製品情報

パンクロニウムブロミド 生産企業

Global(271)Suppliers

パンクロニウムブロミド スペクトルデータ(MS)

15500-66-0, パンクロニウムブロミド キーワード